Maggie L. Shaw

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

Since its founding in 2012, the National Association of ACOs has evolved from a group of 30 to 477 accountable care organization members covering 9.2 million beneficiary lives.

A new report from The Commonwealth Fund compares trends in health plan spending and employee costs for 2014 through 2023 between small and large businesses, taking into account plan premiums, employee contributions, and deductibles. It also highlights that although small firms do not even have to offer health benefits, large firms are required to do so by the Affordable Care Act.

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome treatment resistance in non–small cell lung cancer.

In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of Dermatology, he discusses the benefits of subcutaneous treatment of hidradenitis suppurativa, the chronic inflammatory skin condition.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on epcoritamab, currently being investigated in the Epcore NHL-1 trial.

National Recovery Month is recognized each year in September, and for 2024, we marked the month with a special podcast and exclusive video series with our Strategic Alliance Partner, UPMC Health Plan.

Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).

In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

On Friday, President-elect Donald Trump announced his nominations to lead the CDC, for FDA Commissioner, and for Surgeon General.

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.

Coverage from the IVBM event with Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).

Coverage from the IVBM Regional event in Boston, Massachusetts.

This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).